| Name | Title | Contact Details |
|---|
GeNOsys (generated nitric oxide systems) Inc. is a medical research and development company specializing in pharmaceutical, biotechnical and medical gas
Eupraxia is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to currently approved drugs. Each of Eupraxia`s product candidates has the potential to address therapeutic areas with high unmet medical need, and strives to provide improved patient benefit by delivering targeted, long-lasting activity with fewer side effects. In addition to Eupraxia`s lead product candidate, EP-104IAR, Eupraxia is developing a pipeline of earlier-stage long-acting formulations. Potential pipeline candidates include a range of drugs for indications such as post-surgical pain (EP-105), and post-surgical site infections (EP-201), each designed to improve on the activity and tolerability of approved drugs. Eupraxia is also developing a formulation of EP-104IAR for use in canine and equine osteoarthritis.
Eisai Inc. is a U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., a research-based human health care (hhc) company that discovers, develops and markets products throughout the world.
P.E.C.S. is a Canovanas, PR-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Abivax is a clinical stage biopharmaceutical company that focuses on developing treatments for inflammatory diseases, viral infections, and cancer by modulating the bodys natural immune system machinery.